Truist raised the firm’s price target on NextGen Healthcare to $23.95 from $18 and keeps a Hold rating on the shares. The analyst states that the price target increase reflects the latest deal price for the company after the announcement that it is being acquired by Thoma Bravo at $23.95 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NXGN:
- NextGen Healthcare downgraded to Neutral from Overweight at Cantor Fitzgerald
- NextGen Healthcare downgraded to Neutral from Buy at Guggenheim
- NextGen Healthcare downgraded to Equal Weight from Overweight at Stephens
- NextGen (NASDAQ:NXGN) Jumps on Acquisition Deal with Thoma Bravo
- NextGen Healthcare to be acquired by Thoma Bravo for $23.95 per share in cash
